MORRISVILLE — The CEO of Liquidia Technologies Inc., a clinical stage biopharmacuetical company, was paid $4 million in total compensation in 2018, a large increase from his compensation of $587,000 in 2017.
Liquidia went public in July 2018 for some $50 million.
Neal Fowler has served as CEO since 2008. Before coming to Liquidia, he served seven years as the president of Centocor Inc., a subsidiary of Johnson & Johnson, specializing in the development of biomedicines used to treat chronic inflammatory diseases.
According to a filing with the Securities and Exchange Commission, Fowler’s 2018 compensation jumped to $4 million. The main difference being the $3 million in company stock options he received over the past year.
His base salary increased 14 percent, rising from $411,769 to $478,692 in 2018.
Robert Lippe, chief operations officer of Liquidia, also saw an increase in his 2018 compensation. His salary rose to $868,158 in 2018, including $285,488 in stock options. His base salary increased by 3 percent, rising from $397,048 to $408,960 in 2018.
The company’s annual meeting will be held on May 9 at its executive offices in Morrisville.
Liquidia’s shares closed on Friday at $11.38, up 48 cents.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
Liquidia Technologies closes IPO with $50M in gross proceeds
